Protein interactions with platinum–DNA adducts: from structure to function

Hijacking of the mismatch repair system to cause CAG expansion and cell death in neurodegenerative disease

“…The O 6 -methyl-G [O 6 -meG] DNA adducts induce cell cycle arrest and apoptosis in a manner requiring the DNA mismatch repair [MMR] proteins MutSα and MutLβ [1][2][3][4][5][6]. MSH2/MSH6 also recognizes mismatches containing 8-oxoguanine [87] and cis-Platinum [Pt] [105][106][107]. The most abundant lesion generated by cisplatin is 1,2-d[GpG] intrastrand cross-link formed by the cross-linking of a platinum residue with the N-7 atom of two adjacent guanine residues [105].…”

“…MSH2/MSH6 also recognizes mismatches containing 8-oxoguanine [87] and cis-Platinum [Pt] [105][106][107]. The most abundant lesion generated by cisplatin is 1,2-d[GpG] intrastrand cross-link formed by the cross-linking of a platinum residue with the N-7 atom of two adjacent guanine residues [105]. This lesion can give rise to a compound lesion, namely an intrastrand adduct in one strand and a mismatch in the other [106].…”

MicroRNA-30a Sensitizes Tumor Cells to cis-Platinum via Suppressing Beclin 1-mediated Autophagy

“…In this study, we utilized cis-dichloride diamine platinumtreated (28,29) mice and cells as animal and cellular models, respectively, to characterize the chemotherapy-treatment induced reduction of miR-30a in cancer cells. We determined a role for miR-30a in the suppression of beclin 1-mediated autophagy in cancer cells and sensitization of cancer cells to chemotherapy treatment.…”

Determination of Pt–DNA adducts and the sub-cellular distribution of Pt in human cancer cell lines and the leukocytes of cancer patients, following mono- or combination treatments, by inductively-coupled plasma mass spectrometry

“…Oxaliplatin, a complex consisting of a platinum centre bound to two bidentate ligands; oxalate and a diaminocyclohexane (dach), is a third-generation anti-tumour agent that is used for treating colorectal cancer [11][12][13] and has been successful in treating cell lines and tumours that have developed resistance to cisplatin and other platinum based anticancer drugs [12][13][14]. Oxaliplatin also produces side effects such as haematological suppression and neuropathy [15], although it has been suggested that these effects are less pronounced relative to cisplatin [13,14,16].…”